InflaRx IFRX 深 滬
已收盤 08-07 16:00:00 美东时间
1.84
+0.120
+6.98%
華盛通- 最 高1.905
- 今 開1.81
- 成交量 116.74万股
- 最 低 1.78
- 昨 收 1.72
- 總市值 2.71亿
- 52周最高 2.9489
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 0.7984
- 委 比 17.29%
- 總股本 1.47亿
- 歷史最高 53.10
- 量 比 1.78
- 振 幅 7.27%
- 歷史最低 0.7113
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
08-07 20:30
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 05:20
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per share from the same period last year.
08-06 19:33
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V., a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, will release its Q2 2026 financial and operational results on August 6, 2026, before market open. No conference call is scheduled. The company specializes in C5a and C5aR inhibitors, with lead programs izicopan and vilobelimab for inflammatory diseases. Founded in 2007, InflaRx has offices in Germany and the U.S.
07-30 11:30
InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessmen...
06-30 19:37
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx is evaluating the feasibility of expanding its development and regulatory strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke Tavneos' marketing authorization. The company plans to engage with EMA regarding its anti-C5a antibody vilobelimab and next-generation oral C5aR inhibitor izicopan to assess the most efficient regulatory pathway for approval. Vilobelimab, approved under exceptional c...
06-30 11:30
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
05-11 21:47
美股牛股 | 伟创力绩后暴涨近40%！NNE大涨27%，与超微电脑联手探索核能AI数据中心
伟创力绩后暴涨近40%！宣布分拆云计算部门独立上市；NNE大涨27%，与超微电脑联手探索核能AI数据中心>>
05-07 19:09
